ReviewCurrent heart failure reports2025
Geographic Variations, Peculiarities, and Management of Heart Failure in Sub-Saharan Africa.
Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewHeart failure is a complex cardiovascular syndrome with diverse etiologies. It is prevalent and has a substantial adverse global health impact. This review focuses on the peculiarities of HF in sub-Saharan Africa.
findingsHeart failure poses a significant challenge in sub-Saharan Africa, primarily affecting young adults aged 36.5 to 61.5 years. Patients often present with advanced symptoms, exacerbated by socioeconomic factors and other complications. Key risk factors include hypertension, diabetes, chronic kidney disease, and chronic obstructive pulmonary disease, with new challenges arising from obesity, air pollution, and infectious diseases, further complicating treatment approaches. Diagnostic capabilities in sub-Saharan Africa remain limited. Non-adherence to prescribed medications ranges between 23.7% and 74.7%, worsening disease progression and leading to increased rehospitalizations and mortality rates. Moreover, the high costs of guideline-recommended medications, including sodium-glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitors, restrict their availability. Additionally, advanced device therapies like implantable cardioverter-defibrillators and cardiac resynchronization therapy are often inaccessible due to their high costs, the scarcity of invasive cardiac laboratories, and a limited number of trained healthcare professionals. Heart failure poses a significant challenge in sub-Saharan Africa, especially among younger adults. Late clinical presentations, compounded by socioeconomic barriers, underscore the urgent need for improved healthcare access and education. Addressing key risk factors, enhancing diagnostics, and ensuring treatment adherence are vital for better management. Additionally, the high costs of advanced medications highlight the necessity for more affordable healthcare solutions to alleviate the burden of heart failure in the region.
Indexed as
Identifiers
41134497What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.